Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Based on its cash, cash equivalents, and investments as of December 31, 2025, the Company has extended its cash runway into the first quarter of 2028. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Allogene Therapeutics Q4 2025 Earnings Preview Allogene upgraded at Citizens on discounted EPS, revenue multiple Seeking Alpha's Quant Rating on Allogene Therapeutics Historical earnings data for Allogene Therapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.MarketBeat
- Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.MarketBeat
- Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update GlobeNewswire
ALLO
Earnings
- 3/12/26 - Beat
ALLO
Sec Filings
- 3/12/26 - Form S-8
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- ALLO's page on the SEC website